Phase 1/2 study of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory classic Hodgkin lymphoma: Part 3 (concurrent dosing) results and updated progression-free survival results from parts 1 and 2 (staggered dosing) Meeting Abstract
| Authors: | Advani, R. H.; Moskowitz, A. J.; Bartlett, N. L.; Vose, J. M.; Ramchandren, R.; Feldman, T. A.; LaCasce, A. S.; Christian, B. A.; Ansell, S. M.; Moskowitz, C. H.; Fenton, K.; Ogden, C. A.; Taft, D.; Zak, D. E.; Sacchi, M.; Galderisi, F.; Herrera, A. F. |
| Abstract Title: | Phase 1/2 study of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory classic Hodgkin lymphoma: Part 3 (concurrent dosing) results and updated progression-free survival results from parts 1 and 2 (staggered dosing) |
| Meeting Title: | 60th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 132 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2018 Dec 1-4 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2018-11-29 |
| Language: | English |
| ACCESSION: | WOS:000454837605012 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood-2018-99-110002 |
| Notes: | Meeting Abstract: 1635 -- Source: Wos |
